Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab followed by CHOP + G-CSF for post-transplant lymphoproliferative disorder
2005-000743-29Phase 2Completed
- Sponsor
- Heads
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD) and diffuse large B-cell lymphoma (DLBCL), sponsored by Heads. Started Jun 2009; status: completed.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-000743-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000743-29.